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Interferon- γ (IFN- γ ) 
a b s t r a c t 
Cytokines mediate and control immune and inflammatory responses. Complex interactions exist among 
cytokines, inflammation, and the innate and adaptive immune responses in maintaining homeostasis, 
health, and well-being. On-demand, local delivery of anti-inflammatory drugs to target tissues provides 
an approach for more effective drug dosing while reducing the adverse effects of systemic drug deliv- 
ery. This work demonstrates a proof-of-concept theranostic approach for inflammation based on analyte- 
kissing induced signaling, whereby a drug (in this report, aspirin) can be released upon the detection 
of a target level of a proinflammatory cytokine ( i.e. , interferon- γ (IFN- γ )) in real time. The structure- 
switching aptamer-based biosensor described here is capable of quantitatively and dynamically detecting 
IFN- γ both in vitro and in vivo with a sensitivity of 10 pg mL −1 . Moreover, the released aspirin triggered 
by the immunoregulatory cytokine IFN- γ is able to inhibit inflammation in a rat model, and the release 
of aspirin can be quantitatively controlled. The data reported here provide a new and promising strat- 
egy for the in vivo detection of proinflammatory cytokines and the subsequent therapeutic delivery of 
anti-inflammatory molecules. This universal theranostic platform is expected to have great potential for 
patient-specific personalized medicine. 
Statement of Significance 
We developed an adaptive in vivo sensing device whereby a drug, aspirin, can be released upon the de- 
tection of a proinflammatory cytokine, interferon- γ (IFN- γ ), in real time with a sensitivity of 10 pg mL −1 . 
Moreover, the aspirin triggered by IFN- γ depressed inflammation in the rat model and was delivered in- 
directly through blood and cerebrospinal fluid or directly to the inflammation tissue or organ without 
adverse gastrointestinal effects observed in the liver and kidney. We envision that, for the first time, pa- 
tients with chronic inflammatory disease can receive the right intervention and treatment at the right 
time. Additionally, this technology may empower patients to monitor their personalized health and dis- 
ease management program, allowing real-time diagnostics, disease monitoring, and precise and effective 
treatments. 
© 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. 
∗ Corresponding author. 
E-mail addresses: chenx2015@xjtu.edu.cn (X. Chen), guozhen.liu@unsw.edu.au 
(G. Liu). 
1 Chaomin Cao and Ronghua Jin contributed equally to this work. 
1. Introduction 
Inflammation is a self-protection defense mechanism that is 
critical to combat harmful stimuli ( e.g. , pathogens) and initiate 
the healing process. However, under many conditions, the in- 
flammatory response becomes chronic and leads to significant 
https://doi.org/10.1016/j.actbio.2019.10.021 
1742-7061/© 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. 
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tissue/organ damage. [1] Recently, increasing evidence demon- 
strates that an abnormal inflammatory response is closely associ- 
ated with many cancers [2] and numerous autoimmune diseases 
[3] including rheumatoid arthritis, atherosclerosis, inflammatory 
bowel disease, systemic lupus erythematosus, type 2 diabetes, and 
Alzheimer’s disease. Inflammation is caused by a number of phys- 
iological reactions triggered by the immune system in response to 
a physical injury or an infection. However, the precise source of 
the inflammatory stimulus is often unknown and, even if known, 
may be difficult to remove or inhibit. Thus, interest has been 
shown toward therapeutically targeting the inflammatory response 
to inhibit and limit disease progression. Ongoing disease manage- 
ment in the context of chronic inflammation is increasing, with 
major unmet needs in the era of precision diagnostics and treat- 
ment. [4] Although there has been success with anti-inflammatory 
therapy in chronic diseases such as rheumatoid arthritis, there are 
considerable limitations because of the toxicity associated with 
treatment and variation in patient response. In particular, as the 
inflammatory response is critical for host homeostasis, the chal- 
lenges of redundancy, compensation by the host, and the necessity 
for basal immune function often narrow the risk-to-benefit ratio 
of anti-inflammatory drugs. Thus, it is essential for patients with 
chronic inflammatory disease to receive treatments that target the 
abnormal immune response in a timely and precise manner. 
Precision medicine is a medical model that aims for the cus- 
tomization of healthcare with medical decisions, practices, and 
products tailored to the individual patient. On the basis of the 
knowledge of disease mechanisms, precision medicine generally 
combines diagnosis and treatment to achieve optimal disease man- 
agement [5] . The paradigm of intelligent personalized medicine 
holds the promise to revolutionize healthcare by delivering “the 
right drug, at the right dose, and at the right time” [6] . As stated 
above, precision medicine is particularly important in addressing 
individual inflammation [7] and inflammation-based diseases 
[8] . To meet the needs of precision medicine with an approach 
that can be applied to many individuals without the need for 
specialized and costly individualized therapies, we report here the 
development of a technology that meets this targeted goal. 
In this report, we have utilized aptamer technology to mon- 
itor and measure the host inflammatory response. Aptamers are 
oligonucleotides or peptides that can bind to their targets with 
high affinity and specificity [9] . Aptamers, as a potent and specific 
alternative to antibodies, not only have all of the advantages of 
specific interactions with their target molecules but also have 
unique merits including thermal stability, low production cost, 
lack of immunogenicity, ease of chemical synthesis and modi- 
fication, rapid tissue penetration, and unlimited applications in 
diagnostics and therapeutics [10] . Aptamer beacons can reversibly 
load and release a molecular cargo upon binding to a specific 
target analyte [11] . This feature can be deployed for real-time 
sensing, [12–14] computing, actuating, or drug delivery [15–17] , 
thus moving aptamer-based precision medicine closer to reality. 
For example, Ricci and coworkers demonstrated the construction 
of a modular DNA-based nanomachine that can reversibly load 
and release the nucleic acid upon binding to a specific antibody. 
[18] The antibody-powered DNA nanomachines have demonstrated 
great potential in applications including controlled drug release, 
point-of-care diagnostics, and personalized medicine. [19] 
Cytokines, which act as mediators and modulators in the 
differentiation, sensitization, and activation of various immune 
cells, are bioactive soluble proteins produced by the immune 
and nonimmune cells that are directly required for normal host 
immune function as well as disease initiation and progression 
[20 , 21] The elevated concentration of cytokines in the host serum 
or at specific locations (e.g., a solid tumor) normally indicates the 
activation of inflammation or other steps in disease progression 
[22] . Thus, for patients with chronic inflammatory disease or 
cancer to receive treatment at the right time, it will be essen- 
tial to monitor cell functions and cell-to-cell communication, as 
measured by cytokine expression, and then initiate precision drug 
delivery according to the in vivo cytokine concentration. However, 
there are many challenges in meeting this objective, including the 
fact that cytokine-related immune reactions are often extremely 
dynamic and may be transient and/or localized in nature. [22] In 
addition, cytokines are either not detectable or only expressed at 
picomolar concentrations in body fluid or tissues of healthy indi- 
viduals. We have successfully achieved the sensitivity in pg mL −1 
range of cytokine measurement by introducing nanomaterials to 
the sensing interfaces. [23–25] To realize real-time detection of 
cytokines, we have developed different sensing platforms based on 
aptamers for the detection of cytokines. [26 , 27] Taking advantage 
of the structure-switching property of aptamers, we recently 
reported a structure-switching aptamer-based recyclable in vivo 
sensing device for the continuous detection of the cytokine IFN- γ
in mice at a sensitivity of 1 pg mL −1 . [28] In this system, redox 
probes were loaded in the hairpin part of the aptamer, which 
were released upon the detection of IFN- γ . It was observed that 
the released redox probes could be reloaded to aptamers to realize 
the regeneration of the sensing interfaces. Inspired by this system, 
we are interested in developing a smart stimuli-responsive system 
that can enable continuous cytokine monitoring with a high 
sensitivity while drug delivery is triggered when in vivo cytokine 
levels reach a pathological or “alarmed” level. 
Nonsteroidal anti-inflammatory drugs such as aspirin are 
among the earliest agents used in western medicine. Pharmaco- 
logical effects of aspirin are thought to occur through covalent 
modification of cyclooxygenase (COX) [29] . In this report, we 
developed an adaptive in vivo sensing devices ( Fig. 1 ) based on 
a glassy carbon (GC) rod, which provides an approach whereby a 
drug, aspirin, can be released upon the detection of a target level 
of the proinflammatory cytokine interferon- γ (IFN- γ ) in real time. 
The sensor described here is capable of quantitatively and dynam- 
ically detecting IFN- γ both in vitro and in vivo at a sensitivity of 
10 pg mL −1 . Moreover, the released aspirin triggered by IFN- γ
depresses inflammation in a rat model. We demonstrate here that 
aspirin loaded in aptamers and delivered indirectly through blood 
and cerebrospinal fluid or directly to a tissue or organs can avoid 
adverse gastrointestinal effects and other adverse effects observed 
in the liver and kidney. With our approach, we aim, for the first 
time, that patients with chronic inflammatory disease can receive 
the right intervention and treatment at the right time. Additionally, 
this technology may empower patients to precisely monitor their 
personalized health and disease management through real-time 
diagnostics and disease/treatment monitoring. 
2. Experimental section 
2.1. Chemical and materials 
Aspirin, streptavidin, Tris(hydroxymethyl)aminomethane 
(Tris), hydrochloric acid, potassium chloride, magnesium 
chloride, sodium nitrite, potassium ferricyanide, 1-ethyl-3- 
(3-dimethylaminopropyl)carbodiimidehydrochloride (EDC), 4- 
carboxyphenyl aryldiazonium salt, N-hydroxysuccinimide (NHS), 
2-(N-morpholino)ethanesulfonic acid (MES), and lipopolysaccha- 
ride (LPS) were purchased from Sigma-Aldrich. Phosphate buffer 
solution contained 0.05 M KCl and 0.05 M K 2 HPO 4 /KH 2 PO 4 ad- 
justed to pH 7.4 with NaOH or HCl solution. Aqueous solutions 
were prepared using Milli-Q water. Recombinant human IFN- γ
was purchased from R&D Systems (Minneapolis, MN, USA). All 
DNA was produced by Shanghai Sangon Biotech Co. Ltd. (Shanghai, 
China). The sequence of the hairpin aptamer probe (red color is 
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Fig. 1. Schematic of the fabricated adaptive in vivo device for monitoring IFN- γ and IFN- γ -triggered drug delivery. 
the sequence that has affinity to both human and murine IFN- γ ) 
was 5 ′ -Fc-C 6 -GGG GTT GGT TGT GTT GGG TGT GTC CAA CCC 
C-C 3 -biotin-3 
′ . Tris-HCl buffer contained 100 mM Tris-HCl, 100 mM 
NaCl, 1 mM MgCl 2 , and 5 mM KCl, pH at 7.4. 
2.2. Apparatus 
All electrochemical experiments were conducted with CHI660E 
(CH Instruments, Inc., Shanghai). GC electrodes were 3 mm disks 
embedded in epoxy resin (Gaoss Union, China). All experiments 
used a Pt secondary electrode and an SCE (saturated calomel elec- 
trode) reference electrode. X-ray photoelectron spectra (XPS) were 
recorded from GC plates on a VG MultiLab 20 0 0 spectrometer with 
a monochromatic Al K α source, hemispherical analyzer, and mul- 
tichannel detector. The spectra were analyzed using XPSPEAK41 
software. UV–Vis absorption data were recorded on a Shimadzu 
UV–Vis spectrophotometer model 2450. 
2.3. Preparation of aptamer(aspirin) probes 
To prepare the aptamer(aspirin) probes, 100 μL of 20 μM 
aspirin-containing water solution was mixed with 100 μL of 5 μM 
IFN- γ aptamer probe solution, and the mixture solution was in- 
cubated in Tris-HCl buffer solution (pH = 7.4) at room temperature 
for 24 h. After reaction, the sample was filtered using a centrifugal 
filter (Millipore, Amicon Ultra-0.5 mL 30 K) to wash and purify 
the aptamer (aspirin). The achieved aptamer(aspirin) probes were 
stored at 4 °C before use. 
2.4. Preparation of the sensing interface for detection of IFN- γ
The GC electrodes were cleaned by being hand-polished on 
microcloth pads in 1.0, 0.3, and 0.05 μm alumina slurries in suc- 
cession (made from dry alumina and water), and then they were 
thoroughly rinsed with water and sonicated in water for 1 min. 
Before modification with aryldiazonium salts, the GC electrode was 
dried under a stream of nitrogen followed by exposure to 0.5 M 
HCl solution containing 1 mM corresponding diazonium salts, 
which was degassed for 15 min with nitrogen flow in an ice bath. 
The electrochemical reductive modification of the GC electrodes 
with 4-carboxyphenyl (HOOC-ph-GC) was achieved by scanning in 
the potential range from 0.6 V to −1.0 V for 2 cycles with a scan 
rate of 100 mV s −1 . After washing with water and finally drying 
under a stream of nitrogen, the carboxylic group-terminated 
GC surfaces (GC-ph-COOH) were immersed in 10 mM EDC and 
40 mM NHS prepared in 100 mM MES buffer solution for 1 h to 
activate the carboxylic acid group on the electrode surface. After 
rinsing with deionized water and Tris-HCl buffer solution, the ac- 
tivated electrodes were dried under N 2 , followed by incubation in 
200 μg mL −1 streptavidin (STR) in pH = 7.4 Tris-HCl buffer solution 
at room temperature for 4 h to obtain GC-ph-STR surfaces. Finally, 
GC-ph-STR surfaces was immersed into 5 μM aptamer(aspirin) 
solution for 1 h to generate GC-ph-STR-aptamer(aspirin) surfaces 
for the detection of IFN- γ . 
2.5. Electrochemistry measurement of IFN- γ using the 
aptamer(aspirin)-modified sensing interface 
The prepared GC-ph-STR-aptamer(aspirin) surfaces were incu- 
bated with 10 μL Tris-HCl buffer containing IFN- γ at various con- 
centrations for 30 min at room temperature. Then the squarewave 
voltammetry (SWV) of aptamer(aspirin)-modified GC electrodes 
after exposure to IFN- γ was collected using a CHI660E workstation 
by scanning the potential between −0.2 V and 1.2 V with a step po- 
tential of 4 mV, a frequency of 10 Hz, and an amplitude of 40 mV. 
Real-time measurement was carried out by chronoamperometry in 
a series of different concentrations of IFN- γ by fixing the potential 
at 0.2 V for 50 0 0 s for Fc and 0.9 V for 50 0 0 s for aspirin. 
2.6. Cell culture 
Informed consent in this study was obtained under approved 
Animal Research Ethics Committee protocols with the ethics 
number 2017065. Peripheral blood mononuclear cells (PBMCs) 
were purchased from Procell (Wuhan, China). The cells were 
cultured in a T25 cm 2 flask in RPMI-1640 medium supplemented 
with 10% heat-inactivated human serum AB, 10 U mL −1 of peni- 
cillin, 10 0 0 U mL −1 IL-2, 1100 μg mL −1 of streptomycin,10 μg mL −1 
gentamicin, 2 mM gentamine, and 25 mM HEPES. The cells, at a 
concentration of 1 × 10 6 /mL, were incubated in a 6-well plate at 
37 °C and 5% CO 2 . To harvest, the cells at 80–90% confluence were 
washed twice with Dulbecco’s phosphate-buffered saline, followed 
by trypsinization using 2 mL of trypsin to detach the cells from 
the flask. The trypsin was neutralized by adding 4 mL of fresh 
supplemented medium, and the harvested cells were resuspended 
in complete RPMI-1640 medium, transferred into a centrifuge 
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Fig. 2. (a) Electrochemistry of aptamer(aspirin) probes and aspirin in pH = 7.4 Tris–HCl buffer solution. (b) UV–Vis spectra of aptamer (5 μM), aspirin (50 μM), and ap- 
tamer(aspirin) (5 μM) in pH = 7.4 Tris–HCl buffer solution. 
tube, and centrifuged at 1500 rcf for 10 min. The supernatant 
was discarded, and the cells were resuspended in fresh medium. 
For the preparation of IFN- γ samples, the cells at a density of 
1 × 10 6 /mL were suspended in 1 mL of warm complete medium 
containing 0.1 μg mL −1 LPS to induce IFN- γ expression at 0 h, 2 h, 
4 h, 6 h, 8 h, and 20 h. The supernatants from cells were collected 
in triplicate. The Nunc MaxiSorp 96-well plate and the Galaxy 
plate reader were used for subsequent ELISA. 
2.7. Animal model of endotoxemia 
Adult wild-type Sprague Dawley male rats were purchased 
from Vital River Corporation (Beijing, China). The rats were ran- 
domly divided into two groups (number of animals/group) as (1) 
the control group (no electrode implant) and (2) the electrode 
implant group for corresponding time points at 0 h, 1 h, 6 h, 12 h, 
and 24 h after induction of endotoxemia. Surgery was performed 
under anesthesia by inhalation of 4% isofluorane, and the ani- 
mals were maintained in 2% isofluorane. To induce endotoxemia, 
LPS (5 mg/kg) was injected intraperitoneally. After injection, the 
aspirin-loaded electrodes were implanted into the subcutaneous 
pockets on the back of the animals, and the skin was closed 
with sutures. The animals were euthanized with CO 2 at 0 h, 1 h, 
6 h, 12 h, and 24 h, and the blood and electrodes were harvested 
for analysis. As the lung is the moderately affected tissue in 
endotoxemia, the lungs were collected for histological analysis 
at 24 h. 
2.8. ELISA assays 
To evaluate the effects of aspirin-loaded electrodes, the blood 
specimens of the two groups of rats and the interstitial fluid of 
the lung were collected and processed immediately for further 
cytokine measurement. The levels of inflammatory cytokines (IL-6 
and IFN- γ ) in the serum and fluid were measured using the 
enzyme-linked immunosorbent assay (ELISA) kit (Boster Biological 
Technology, China) according to the manufacturer’s instructions. 
2.9. Histology and immunohistochemistry assay 
The lungs from experimental groups of rats were collected, 
fixed in 10% formalin overnight, embedded in paraffin, and sec- 
tioned at a thickness of 5 μm. The sections were deparaffinized, 
rehydrated, and stained with hematoxylin and eosin (H&E). More- 
over, the sections were also stained with a neutrophil marker (Ly- 
6 G antibody, Thermo Fisher Scientific, USA) for immunohistochem- 
istry measurement. The procedure was carried out according to the 
protocol of the atreptavidin-peroxidase immunohistochemical kit 
with antimouse Ly-6 G/Gr-1 antibodies (1:200, Santa Cruz Biotech- 
nology), followed by antimouse IgG-horseradish peroxidase- 
conjugated secondary antibody (1:200, Jackson), and the 3,3 ′ - 
diaminobenzidine (DAB) coloration kit (Zhongshan Bioengineering 
Co. Ltd, Beijing, China). The immunostaining results were observed 
after samples were treated with a hematoxylin counterstain. For 
histopathological analyses, four inflammatory parameters were 
scored independently from 0 to 4 for each section as previously de- 
scribed [30] : alveolar congestion; (b) hemorrhage; (c) neutrophilic 
infiltration, and (d) thickness of the alveolar wall and hyaline 
membrane formation. Each category was graded on a 0- to 4-point 
scale: 0 = no injury; 1 = injury up to 25% of the field; 2 = injury 
up to 50% of the field; 3 = injury up to 75% of the field; and 
4 = diffuse. [31] Injury slides were randomized, read blindly, and 
scored for each. The inflammatory cell number and the positive 
area of IHC staining were evaluated with Image-Pro-Plus software. 
2.10. Statistical methods 
All experiments were performed in at least triplicate, and 
the results were presented as the mean and standard deviation 
of the three replicates. Statistical analyses were performed with 
both Excel and Origin. We considered p < 0.01 as statistical 
significance. 
3. Results and discussion 
3.1. Characterization of aptamer (aspirin) probes 
Initially, the SWVs of GC electrodes in pH = 7.4 Tris-HCl buffer 
solution after applying 10 μL of 20 μM aspirin, 5 μM aptamer, 
and 5 μM aptamer(aspirin) probe were determined. As shown in 
Fig. 2 , a pair of redox peaks was observed for GC electrodes after 
applying the aspirin solution at 0.9 V. However, two pairs of peak 
current were observed after applying the aptamer(aspirin) probe 
on the GC electrode at 0.2 V and 0.9 V, representing ferrocene and 
aspirin, respectively, suggesting that aspirin has been embedded 
into the stem part of the aptamer probe as shown in the schematic 
design in Fig. 1 . This result was confirmed by UV–Vis absorption 
spectroscopy ( Fig. 2 b), as one absorption peak, centered at 260 nm, 
was observed in the UV–Vis absorption spectra of aptamer and 
aptamer (aspirin). Another absorption peak, centered at 295 nm, 
was observed in the UV–Vis absorption spectra of both aspirin 
and aptamer (aspirin) [32] . This result suggested that aspirin 
was successfully intercalated into the double-stranded 5 ′ -GC-3 ′ 
sequences of the aptamer by the force of π–π stacking to confirm 
the aptamer (aspirin) probes [33] . Under optimized conditions, we 
quantified the number of aspirin molecules loaded on the aptamer 
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Fig. 3. (a) C1s spectra for GC-ph-COOH. (b) N1s spectra for GC-ph-COOH. (c) C1s spectra for GC-ph-STR-aptamer(aspirin). (d) N1s spectra for GC-ph-STR-aptamer(aspirin). 
(e) P2p spectra for GC-ph-STR-aptamer(aspirin). (f) GC-ph-STR-aptamer(aspirin) after exposure to 500 pg mL −1 IFN- γ for 30 min followed by washing. (g) XPS survey spectra 
for stepwise modification of the sensing interfaces. 
complex according to the modified protocol [34] . Supplementary 
Figure S1 shows the SWV curves that were obtained by reacting 
100 μL of 5 μM aptamer solution with different concentrations 
of 100 μL aspirin solution for 24 h. The oxidation peak current of 
aspirin increased with the increase in the concentration of aspirin 
from 5 to 100 μM, and it reached a plateau when a concentration 
of more than 20 μM was added. Thus, the optimized concentration 
of the aspirin solution was 20 μM (Supplementary Figure S1 a). 
On the basis of the calibration curve between aspirin concentra- 
tion and absorbance (Supplementary Figure S1 b), the maximal 
absorbance of the aspirin was observed when the ratio of aspirin 
and aptamer reached 3:1, suggesting three aspirin molecules could 
intercalate into one aptamer. To provide more information about 
the loading capacity of aspirin on each electrode, the optimized 
electrode was heated to 95 °C to release all the encapsulated 
aspirin as a result of DNA denaturation. The released aspirin 
was measured by UV–Vis absorption spectroscopy, indicating the 
amount of aspirin on each electrode was approximately 3.1 μmol. 
3.2. XPS characterization of the stepwise fabricated sensing interface 
XPS measurements were carried out to further characterize GC 
surfaces after stepwise modification with different species. C1s has 
two peaks at around 284.7 eV and 288.9 eV. The peak at 288.9 eV 
is assigned to the carbon of the carboxyl groups on the surface of 
GC-ph-COOH ( Fig. 3 a) [35] . However, N1s has two peaks at about 
400.2 eV, which are assigned to unreacted carboxyphenyl ( Fig. 3 b). 
For the GC-ph-STR-aptamer(aspirin) surface, C1s has four peaks 
at around 284.4 eV, 286.1 eV, 287.7 eV, and 291.2 eV ( Fig. 3 c). The 
peak at 286.1 eV is assigned to the –C –O –C- species in streptavidin 
[36] . The peak at 287.7 eV is assigned to the peptide bond formed 
by the interaction between -COOH from 4-carboxyphenyl on 
electrodes and amine from streptavidin [26] . The peak at 291.2 eV 
is assigned to the -COO –CH 3 - species in aspirin [33] . In addition, 
the peak at 133.6 eV was assigned to phosphorus in the aptamer 
DNA ( Fig. 3 e) [37] . The results suggest that aptamer(aspirin) was 
successfully attached onto the GC-ph-COOH surface. However, 
two peaks at 399.7 eV and 401.2 eV were observed in the N1 
species on the GC-ph-STR-aptamer(aspirin) surfaces, and these 
were assigned to unreacted EDC and NHS, respectively ( Fig. 3 d). 
However, the peak of C1s at 291.2 eV disappeared after exposure 
of the aptamer(aspirin)-modified GC surfaces to 500 pg mL −1 
IFN- γ , suggesting that the GC-ph-STR-aptamer(aspirin) surfaces 
could release aspirin in the presence of IFN- γ ( Fig. 3 f). Fig. 3 g 
illustrates XPS survey spectra confirming the successful stepwise 
modification of the sensing interfaces. 
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3.3. Electrochemistry characterization of the stepwise fabricated 
sensing interface 
The stepwise fabrication of the GC-ph-STR-aptamer(aspirin) 
sensing surfaces was also characterized by electrochemistry. The 
first sweep of the electrochemical modification of GC with the 
4-carboxyphenyl groups (Supplementary Figure S1 c) produced an 
irreversible reduction wave at −0.4 V corresponding to the reduc- 
tion of the carboxyl acid group to a radical anion . On the second 
scan, the first wave at −0.4 V vanished, suggesting inhibition of 
the electron transfer by the 4-carboxyphenyl group grafted on the 
GC surfaces. After the modification of 4-carboxyphenyl layers, the 
redox peaks of Fe(CN) 6 
3- observed with bare GC electrodes were 
completely suppressed (Supplementary Figure S1 d), giving strong 
evidence that a monolayer of 4-carboxyphenyl, which blocked the 
access of redox molecules to the GC electrode, had formed on the 
GC surfaces. The SWV curves of bare GC, HOOC-ph-GC, STR-GC, and 
aptamer(aspirin)-GC in PBS buffer are displayed in Supplementary 
Figure S1 e. A redox peak was observed at 0.8 V, which is the char- 
acteristic peak of STR, suggesting that STR was successfully mod- 
ified onto the electrode surface [38] . After modification of the ap- 
tamer(aspirin) onto the GC electrode to form aptamer (GC) through 
the interaction between biotin and streptavidin, a symbolic peak 
from Fc was observed in SWV (Supplementary Figure S1 f). 
3.4. In vitro real-time monitoring of IFN- γ and IFN- γ -triggered 
aspirin release using the GC-ph-STR-aptamer (aspirin) interface 
After the successful fabrication of the GC-ph-STR- 
aptamer(aspirin) sensing interface, the electrochemical response 
of the GC-ph-STR-aptamer(aspirin) sensing interface to IFN- γ was 
analyzed ( Fig. 4 ). In the absence of IFN- γ , there was an obvious 
redox peak observed at 0.2 V, which belongs to a ferrocene-free 
aptamer ( Fig. 4 a). According to the redox peak of Fc in Fig. 4 a, the 
surface coverage of the aptamer was calculated to be 5.1 x How- 
ever, the peak at 0.2 V disappeared, and a pair of redox peaks at 
approximately 0.9 V, characteristic of aspirin, appeared after expo- 
sure to IFN- γ followed by extensive washing. The electrochemical 
signal switching was due to the binding of IFN- γ to the loop part 
of the aptamer, leading to the opening of the stem part of aptamer, 
followed by the subsequent release of aspirin molecules into the 
environment. This then induced the electric communication be- 
tween the released aspirin and the underneath GC electrode, 
resulting in the subsequent Faradic current at 0.9 V. Furthermore, 
Fc redox molecules labeled on aptamers were dissociated away 
from the electrode surface because of the configuration change 
of the aptamer, resulting in decreased electron transfer efficiency 
between the aptamers and underlying electrodes and, consequen- 
tially, switching off of the current. To confirm this hypothesis, 
SWV, as a more sensitive electrochemical technique, was used to 
quantitatively monitor the electrochemical response ( Fig. 4 b). 
The real-time sensor described here is based on analyte- 
kissing-induced structure-switching aptamers and subsequent 
aspirin-releasing signaling molecules. Thus, any factors that affect 
the binding of aspirin to the aptamer will contribute to the sen- 
sor performance. To investigate environmental influences on the 
sensor, the effect of pH, salt concentration, and temperature on 
the stability of the GC-ph-STR-aptamer(aspirin) sensing interface 
(the release of aspirin) was analyzed (Supplementary Fig. S2). It 
was observed that under acidic conditions, the DNA was deprived 
of purines leading to the release of aspirin. Thus, less aspirin was 
released after reaction with IFN- γ , resulting in a smaller current. 
However, when the pH reached 8 (Supplementary Fig. S2 a), the 
aptamer was denatured by the alkaline condition, and that neutral- 
ized the charge of acids but caused the hydrolysis of bases upon 
prolonged treatment. Consequently, pH 7.4 was found to be the 
optimized condition required to monitor IFN- γ levels. The sensing 
provided the optimized performance when the salt concentration 
was 100 mM (Supplementary Figure S2 b). In addition, increasing 
the temperature from 25 °C to 95 °C also caused the release of 
aspirin molecules before reaction with IFN- γ . Heating the ap- 
tamer(aspirin) solution to 95 °C leads to DNA denaturation by sep- 
arating a double strand into two single strands, thus subsequently 
releasing the incorporated aspirin molecules, a process that oc- 
curred when the hydrogen bonds between the DNA strands were 
broken [39] . Consequently, the stem part of the aptamer opens 
and releases the incorporated aspirin molecules (Supplementary 
Figure S2 c). However, the GC-ph-STR-aptamer(aspirin) sensing 
interface performed well at physiological temperature, i.e., 37 °C, 
which makes it stable under physiological conditions. The reaction 
time with IFN- γ was also investigated by monitoring the change 
in current with the reaction time (Supplementary Fig. S2 d). The 
current increased with the reaction time and reached a plateau 
when the reaction time was 60 min. The current at 30 min was ap- 
proximately 90% of that observed at 60 min and thus was selected 
as the optimized reaction time. Under optimized conditions, the 
peak current corresponding to IFN- γ decreased with the increase 
in IFN- γ concentration ( Fig. 4 c). There was a linear range of 10–
500 pg mL −1 for the detection of IFN- γ with the lowest detection 
limit of 10 pg mL −1 in Tris buffer. As determined from the mid- 
point of the IFN- γ calibration curve shown in Fig. 4 d, the affinity 
constant between IFN- γ (molecular weight 16.9 kDa) and the ap- 
tamer(aspirin) was calculated to be approximately 5.3 × 10 10 M − 1 . 
The typical affinity constant K a for antigen–antibody reactions is in 
the range of 10 8 to 10 12 M −1 [40] , and hence, the data presented 
here indicate that the aptamer(aspirin) probe has a very high 
affinity to IFN- γ . Furthermore, the electrochemistry responsible 
for the released aspirin was recorded ( Fig. 4 e), and the SWV peak 
current increased with increasing IFN- γ concentration. The peak 
current at approximately 0.9 V demonstrated a linear relationship 
with the concentration of IFN- γ in the range of 0–500 pg mL −1 . 
This observation indicates that aspirin was released, which can 
be quantitatively measured according to the current change in 
0.9 V. This further confirms that our proof-of-concept system 
for cytokine detection and cytokine-triggered drug delivery was 
effective. 
To investigate the real-time sensing capability of the GC-ph- 
STR-aptamer(aspirin) interface, a chronoamperometry experiment 
at a constant potential of 0.2 V (close to the oxidation potential 
of Fc) was carried out by adding different concentrations of IFN- γ
under constant stirring ( Fig. 5 a). Fig. 5 b shows the calibration 
curve based on the chronoamperometry measurement. The linear 
range obtained here was 10–500 pg mL −1 , which is comparable to 
that obtained by SWV as shown in Fig. 3 d. Upon the addition of 
IFN- γ , the monitored current of the GC-ph-STR-aptamer(aspirin) 
sensing interface decreased with the increase of the IFN- γ concen- 
tration. A chronoamperometry experiment at a constant potential 
of 0.9 V (close to the oxidation potential of aspirin) was carried 
out by adding different concentrations of IFN- γ under constant 
stirring ( Fig. 5 c). Upon the addition of IFN- γ , the monitored 
current of the GC-ph-STR-aptamer(aspirin), in contrast to the 
current observed by a constant potential of 0.2 V, increased with 
increasing IFN- γ concentration. This suggests that the presence 
of IFN- γ induced the configuration change of the aptamer and 
the subsequent release of aspirin, resulting in increased current at 
0.9 V. To confirm the proposed mechanism of the analyte-induced 
drug delivery, we measured the rate of aspirin release in the pres- 
ence of IFN- γ . According to Chow’s method [41] , the drug release 
rate can be calculated using the equation K = ln(C /C 0 ) / (t-t 0 ). In 
the presence of IFN- γ , the rate of aspirin release was calculated 
to be 0.033 μM min −1 , suggesting a quantitatively controlled drug 
release. 
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Fig. 4. (a) Cyclic voltammetries and (b) Squarewave voltammetries of the GC-ph-STR-aptamer(aspirin) sensing interface in pH 7.4 Tris buffer before and after exposure to 
500 pg mL −1 IFN- γ . (c) Spectrum of the Fc peak generated by the SWV of GC-ph-STR-aptamer(aspirin) after exposure to different concentrations of IFN- γ (0, 10, 50, 200, 
30 0, 40 0, 50 0, 80 0, and 10 0 0 pg mL −1 ). (d) The relationship of the peak current of Fc at (c) with the log concentration of IFN- γ . (e) Spectra of the aspirin peak generated by 
the SWV of GC-ph-STR-aptamer(aspirin) after exposure to different concentrations of IFN- γ . (f) The relationship of the peak current corresponding to aspirin in (e) with the 
concentration of IFN- γ . 
To investigate the selectivity of the fabricated sensor, seven 
potentially interfering compounds, namely, bovine serum albu- 
min (BSA, 2 mg mL −1 ), prostate-specific antigen (PSA, 1 μg mL −1 ), 
cancer antigen 125 (CA-125, 1 μg mL −1 ), IL-6 (1 μg mL −1 ), TNF- 
ɑ (1 μg mL −1 ), IFN- α (1 μg mL −1 ), and IFN- β (1 μg mL −1 ), were 
added to the detection buffer solution in the presence of IFN- γ
(500 pg mL −1 ) (Supplementary Figure S2 e). No significant ef- 
fect from these seven nonspecific proteins was detected. The 
retained current percentage for all nonspecific proteins was above 
90%, suggesting an insignificant degree of interference by these 
molecules tested in relation to the control ( < 10%). The stability of 
the sensing interface was also analyzed by incubating the GC-ph- 
STR-aptamer(aspirin) sensing interface in Tris buffer for 1, 2, 3, 5, 
10, 15, 20, 25, and 30 days at room temperature, respectively. The 
electrochemistry was monitored at each time point (Supplemen- 
tary Figure S2 e). Less than 5% of the signal was lost from Fc after 
25 days, indicating that the GC-ph-STR-aptamer(aspirin) sensing 
interface was stable for at least 25 days. 
3.5. Detection of IFN- γ in a cellular microenvironment 
The GC-ph-STR-aptamer(aspirin) sensing interface was tested 
for the detection of IFN- γ secreted by PBMCs ( Fig. 6 ). First, a 
chronoamperometry experiment at a constant potential of 0.2 V 
was carried out in a medium containing 1 × 10 6 cells under 
stirring, to which IFN- γ , at concentrations of 10–10 0 0 pg mL −1 , 
was added ( Fig. 6 a). It was observed that the current decreased 
continuously after adding IFN- γ until it reached a plateau when 
the concentration of IFN- γ was 500 pg mL −1 . The calibration curve 
for real-time measurement of IFN- γ in the cell culture medium 
was plotted as shown in Fig. 6 b. The supernatant of the 1 × 10 6 
PBMCs was collected for IFN- γ analysis after LPS stimulation for 2, 
4, 6, 8, and 12 h. The supernatant samples were subsequently an- 
alyzed by ELISA and prepared for the GC-ph-STR-aptamer(aspirin) 
sensing interface. As shown in Fig. 6 b, the concentration of IFN- γ
increased with the duration of the 10 ng mL −1 LPS treatment, and 
the maximum level of 500 pg mL −1 IFN- γ was obtained after 
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Fig. 5. (a) The current record as a function of time for GC-ph-STR-aptamer(aspirin) in pH = 7.4 Tris–HCl buffer solution at a constant potential of 0.2 V after adding IFN- γ at 
different concentrations. (b) The calibration curve of the GC-ph-GO-aptamer (Ru) sensing interface obtained by the chronoamperometry in (a) and another two independent 
measurements. (c) The current record as a function of time for GC-ph-STR-aptamer(aspirin) in pH = 7.4 Tris–HCl buffer solution at a constant potential of 0.9 V after adding 
IFN- γ at different concentrations. (d) The calibration curve of the GC-ph-GO-aptamer(Ru) sensing interface obtained by the chronoamperometry in (c) and another two 
independent measurements. (e) I-t curves of aspirin at different concentrations of IFN- γ . (f) The standard linear calibration curve of cytokine according to (e) and another 
two independent measurements. 
Fig. 6. (a) Chronoamperometry recording of GC-ph-STR-aptamer(aspirin) sensing cell culture media of PBMCs at a constant potential of 0.2 V after LPS treatment. (b) Cali- 
bration curve of the GC-ph-STR-aptamer(aspirin) sensing interface obtained by chronoamperometry in (a) and another two independent measurements. The inset in (b) is a 
comparison of the IFN- γ secretion profile between the presented sensor and the traditional ELISA after 10 ng mL −1 LPS stimulation. 
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Fig. 7. Reduced Fc currents and increased aspirin currents measured in the blood of rats with inflammation using the GC-ph-STR-aptamer(aspirin) sensor. Currents generated 
at constant potentials of 0.2 V (a) and 0.9 V (b) were measured. 
Fig. 8. Relationship between peak current and implantation time, which was obtained by the SWV measurement of the GC-ph-STR-aptamer(aspirin) device after implantation 
into the inflammatory rat model for different time points, in Tris–HCl buffer with the potential between 0 V and 0.5 V (a) and in Tris–HCl buffer containing 10 0 0 pg/mL of 
IFN- γ with the potential between 0.7 V and 1.2 V (b). (a) Fc signal on the electrode and (b) the residual aspirin on the electrode. The inset shows the release profile of aspirin 
against the implantation time calculated from (b). 
8 h LPS stimulation, a finding that was consistent to what we 
previously reported. [30] A comparison of IFN- γ detection using 
the proposed biosensor device and the traditional ELISA method 
is included in the inset of Fig. 6 b. The sensor reported herein and 
ELISA displayed similar IFN- γ secretion patterns, suggesting that 
the performance of the sensor was comparable with that of ELISA 
for the detection of IFN- γ in a cell microenvironment. 
3.6. Detection of IFN- γ and IFN- γ -triggered aspirin release in blood 
samples 
The performance of the GC-ph-STR-aptamer(aspirin) for the 
detection of IFN- γ and simultaneous aspirin release was investi- 
gated in blood samples obtained from male rats intraperitoneally 
injected with LPS to induce endotoxemia (designated “inflam- 
matory rat”). Blood samples were collected using heparinized 
capillary tubes at 0 h and 24 h after implantation. The GC-ph-STR- 
aptamer(aspirin)-modified in vivo devices were incubated in 1 mL 
of the blood collected from normal rats and the inflammatory 
rat model for 1 h. Then 1 mL of Tris–HCl buffer was added, and 
the chronoamperometry experiment at a constant potential of 
0.2 V (Fc) and 0.9 V (aspirin) was performed utilizing these blood 
samples. As shown in Fig. 7 and Supplementary Figure S3, the 
monitored current of the GC-ph-STR-aptamer(aspirin) for the Fc 
peak in the blood of normal rats was much higher than that 
measured in the blood of the inflammatory rat model, while a 
completely contrasting phenomenon was observed in the current 
for the aspirin peak. This observation suggested that IFN- γ levels 
in the blood of the inflammatory rat model were much higher than 
those measured in the blood of normal rats. These results also 
demonstrated that only IFN- γ in the blood of the inflammatory rat 
model was able to release the aspirin from the GC-ph-STR-aptamer, 
thereby changing the configuration of aptamer to suppress the 
electrochemical signal of Fc. This demonstrated the potential of 
the GC-ph-STR-aptamer(aspirin) sensing device for the integrative 
detection of pro-inflammatory signals and subsequent therapy. 
3.7. Detection of IFN- γ and IFN- γ -triggered aspirin release in living 
rats 
To further investigate the in vivo performance of the GC- 
ph-STR-aptamer(aspirin) device for IFN- γ detection and aspirin 
release, the electrodes were initially implanted into the sub- 
cutaneous tissue of rats treated with LPS for 0–24 h. Then the 
withdrawn electrodes were measured by SWV in Tris-HCl buffer 
with the potential between −0 V and 0.5 V and in Tris-HCl buffer 
containing 10 0 0 pg mL −1 of IFN- γ with the potential between 0.7 V 
and 1.2 V to check the remnant Fc and aspirin signal using pro- 
cedures identical to those detailed above. As shown in Fig. 8 and 
Supplementary Figure S3, the SWV curves and current peak of the 
GC-ph-STR-aptamer(aspirin) devices against the implantation time 
in LPS-treated rats display dramatic peak current drops with time 
extension. The gradually decrease in the Fc and aspirin signals, 
respectively, demonstrated the specific detection of our sensor 
of inflammation (i.e . , IFN- γ expression) and the inflammation- 
triggered aspirin release. Moreover, the difference in peak current 
between the untreated electrode (from the original aspirin) and 
the withdrawn electrodes (from the remnant aspirin) was used to 
calculate the percentage of aspirin release during the treatment. 
The consequence of the in vivo binding of IFN- γ on the GC- 
ph-STR-aptamer(aspirin) electrode was the immediate release of 
aspirin. The relationship between the release percentage of aspirin 
and the treatment time was also obtained ( Fig. 8 ), revealing the 
prospect of the sensor for in vivo detection and subsequent aspirin 
delivery targeted to the treatment of inflammation. As shown in 
the inset of Fig. 8 , the in vivo release efficiency of aspirin could 
reach up to 85.6% after 24 h. Considering that the body weight of 
rats used herein was approximately 180 g, each electrode would 
C. Cao, R. Jin and H. Wei et al. / Acta Biomaterialia 101 (2020) 372–383 381 
Fig. 9. (a) The quantification of inflammatory cells per field of lung tissue. (b-c) Expression level of inflammatory cytokines (IFN- γ and IL-6) in the interstitial fluid of the lung 
tissue by ELISA. (d) Histological analysis indicated that LPS injection caused capillary expansion and congestion, as well as neutrophil infiltration into the lung tissue, while 
the lung injury was well controlled by applying the electrode. The scale bar is 100 μm. (e) Lung injury score increased significantly after LPS administration and significantly 
reduced after electrode treatment ( ∗∗ , p < 0.01 compared with the LPS group). (f) Immunohistochemically identified neutrophils in the lung after LPS administration and 
electrode treatment. Yellow arrows represent the positive area. The scale bar is 100 μm. (g) Score of Ly-6 G protein expression levels increased in the lung sections of two 
groups ( ∗∗ , p < 0.01 compared with the LPS group). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this 
article.) 
release an aspirin level of 2.7 mg/kg in rat blood after 24 h of 
implantation. This aspirin concentration was lower than the ideal 
amount (10 mg/kg/day) used for traditionally anti-inflammatory 
treatment in a murine model [42] . 
3.8. In vivo inflammation control using the adaptive 
GC-ph-STR-aptamer (aspirin) devices 
LPS is the major element of the outer membrane in gram- 
negative bacteria. LPS-induced endotoxemia can lead to serious 
acute lung injury (ALI), which is characterized by an increase in 
capillary permeability and neutrophil migration into the lungs 
[43] . Moreover, exposure to LPS can induce the secretion of ad- 
ditional proinflammatory cytokines, resulting in the activation of 
polymorphonuclear neutrophils (PMNs) and further inflammatory 
responses in the lung [44] . To demonstrate the performance of 
adaptive GC-ph-STR-aptamer(aspirin) in vivo devices, we collected 
lungs from the inflammatory rat model with and without electrode 
implantation for 24 h, and then the quantitative analysis of these 
lung samples was performed to provide evidence for the in vivo 
therapeutic efficacy of our electrode. As shown in Fig. 9 a, the num- 
ber of inflammatory cells was significantly reduced after electrode 
administration under LPS treatment condition. In addition, the 
ELISA results show that the expression of inflammatory cytokines 
(IFN- γ and IL-6) in the interstitial fluid obviously deregulated, 
indicating the effective inhibition of the inflammation ( Fig. 9 b and 
c). These lung samples were also stained with hematoxylin and 
eosin (H&E) for histological analysis and neutrophil marker (Ly-6G) 
for polymorphonuclear (PMN) leukocyte infiltration by immuno- 
histochemistry detection, indicating that PMN cells infiltrated 
more into the lungs of the untreated group 24 h after LPS injection 
than those of the electrode-treated group ( Fig. 9 d and f). Moreover, 
Fig. 9 e and g show that the degree of lung injury was significantly 
improved while the number of neutrophil expression was dramati- 
cally reduced after treatment with our electrode, providing further 
evidence of the therapeutic efficacy of our electrode. 
To further evaluate the therapy, the blood specimens of the 
electrode-treated and untreated inflammatory rat model were col- 
lected for the measurement of the inflammatory cytokines IFN- γ
and IL-6. As shown in Fig. 10 , the levels of inflammatory cytokines 
(IL-6 and IFN- γ ) in the electrode-treated rats have no obvious 
change within 24 h after LPS injection, which is in accordance with 
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Fig. 10. The inflammation induced by LPS (control, untreated group) was inhibited by the GC-ph-STR-aptamer(aspirin) sensor (electrode-treated group) or pure aspirin 
(aspirin-treated group). The concentration of IFN- γ (a) and IL-6 (b) was measured in the serum of the inflammatory rat model with and without treatments. 
the pure aspirin-treated rats. However, the concentration of both 
inflammatory cytokines in rats without treatment dramatically in- 
creased only in several hours. This indicates that the inflammation 
could be effectively and consistently suppressed by application of 
our electrodes. These results revealed that this adaptive GC-ph- 
STR-aptamer(aspirin) in vivo device could achieve the on-demand 
release of aspirin to effectively inhibit inflammation. 
4. Conclusions 
Cytokines, the signaling molecules in the immune system, play 
a key role in mediating and controlling immune and inflamma- 
tory responses. [45] Complex interactions exist among cytokines, 
inflammation, and the adaptive and innate responses to maintain 
normal homeostasis. It is essential to develop accurate and sen- 
sitive methods for the measurement of cytokines in real time to 
dynamically monitor inflammation, and such measurements can 
be an important basis for the proper treatment of developing and 
ongoing disease. [22 , 30 , 46] Recently, there has been increasing 
evidence that an abnormal inflammatory response is closely as- 
sociated with various disease conditions. [1] Thus, interest has 
been shown toward therapeutically targeting the inflammatory 
response. Lack of precise, directed application of therapeutics and 
reduced effectiveness with chronic use are current limitations for 
the treatment of inflammation. To overcome these issues, preci- 
sion or personalized medicine has demonstrated the capability of 
diagnosis and triggered treatment by delivering “the right drug, at 
the right dose, and at the right time” [6] . 
On-demand, local delivery of anti-inflammatory drugs to target 
tissues provides a means for effective drug dosing while reducing 
the adverse effects of systemic drug delivery. The study reported 
here has demonstrated a proof-of-concept theranostic approach for 
inflammation based on analyte-kissing-induced signaling whereby 
a drug (in this report, aspirin) can be released upon the detection 
of a target level of a proinflammatory cytokine (i.e., interferon- γ
(IFN- γ )) in real time. The structure-switching aptamer-based 
biosensor described here is capable of quantitatively and dynam- 
ically detecting IFN- γ both in vitro and in vivo with a sensitivity 
of 10 pg mL −1 . Moreover, the released aspirin triggered by the 
inflammatory cytokine IFN- γ is able to inhibit inflammation in a 
rat model, and the release of aspirin can be quantitatively con- 
trolled. This study is a an advancement of our previous study that 
reported a sensitive sensing device for monitoring inflammation 
in mice. [30] In our previous report, the positively charged redox 
probes (ruthenium hexamine), acting as the signaling molecules, 
were loaded into the structure-switching aptamers. The presence 
of IFN- γ triggers the release of redox probes, resulting in an 
electrochemical signal that measures the concentration of IFN- γ . 
Although the sensitivity of this sensor is high, this in vivo sensing 
device has three limitations: 1) it cannot act as a real-time sen- 
sor, 2) the release of redox probes into the mice might cause a 
potential safety problem, and 3) it does not have the therapeutic 
function of the device reported in this study. 
Specifically, here we prepared the adaptive device based on 
the aspirin intercalating hairpin aptamer that can realize the 
spatially localized monitoring of IFN- γ in real time along with the 
simultaneous delivery of aspirin. Furthermore, the performance of 
this adaptive device has been investigated in vitro , in cell culture 
medium, in blood samples, and in the serum of LPS-treated rats. 
To the best of our knowledge, this is the first study to provide 
a technology for the in vivo real-time monitoring of proinflam- 
matory cytokines and the subsequent therapeutic delivery of 
anti-inflammatory molecules. Thus, this report provides a new and 
promising strategy for the precision theranostic of inflammation. 
By varying the aptamer probes targeted to different analytes 
(such as cancer biomarkers) and also the availability of small 
therapeutic drugs (such as doxorubicin), this universal theranostic 
platform has significant potential for personalized medicine and 
the effective treatment of numerous health conditions. 
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